A Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of JYP0066 Topical Cream in Adolescents and Adults With Mild-to-Moderate Atopic Dermatitis

This is a Phase 2 research study testing an investigational topical cream called JYP0066 for the treatment of mild-to-moderate atopic dermatitis (eczema) in teenagers (12-17 years old) and adults. The study will check whether JYP0066 cream can reduce eczema signs and symptoms such as redness, itching, dryness, and skin thickening, and whether it is safe and well tolerated.

Participants will be randomly assigned to one of four groups: they will apply either 4%, 3%, or 2% JYP0066 cream, or a matching placebo cream, to eczema-affected skin twice a day for 8 weeks. All creams will look the same. This helps the study compare which concentration works best and how safe each one is.

Study Overview

• Status: Not yet recruiting
• Conditions: Atopic Dermatitis (AD)
• Intervention / Treatment: Drug: JYP0066 4% topical cream; Drug: 3% JYP0066 topical cream; Drug: 2% JYP0066 topical cream; Drug: Matching placebo cream (vehicle, no active ingredient)

• Study Type: Interventional
• Enrollment (Estimated): 160
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years to 75 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Participant is ≥12 and ≤75 years of age at the time of signing informed consent; male or female.

Note: Participants who are ≥12 and <18 years of age at screening and baseline will be classified as adolescents throughout the study.

Body weight ≥40 kg. Meets Williams diagnostic criteria for atopic dermatitis (AD) at screening and baseline, with AD onset at least 6 months before screening.

Williams criteria - Major criterion: itchy skin. Minor criteria: (a) history of flexural dermatitis (elbow/antecubital, popliteal, anterior ankle, neck; in children <10 y, cheek rash); (b) history of asthma or allergic rhinitis (or atopic disease in first-degree relatives for children <4 y); (c) generalized dry skin in recent years; (d) flexural eczema (in children <4 y: cheek/forehead/extensor eczema); (e) onset before age 2 (for patients ≥4 y). Diagnosis = major criterion + ≥3 minor criteria.

vIGA-AD score of 2 (mild) or 3 (moderate) at both screening and baseline. Total AD lesion area of 3%-20% body surface area (BSA) at screening and baseline.

Note: Lesions on scalp, face, and genital area are excluded from BSA calculation at screening and baseline.

Females of childbearing potential must have a negative serum pregnancy test at screening. All participants of childbearing potential (and their partners) must agree to use highly effective contraception from informed consent through 1 month after last study drug administration and must not donate sperm/ova during this period.

Note: Applies also to post-menarchal female adolescents and post-semenarche male adolescents.

Adults: able to understand the purpose and procedures of the study, voluntarily provide written informed consent, and comply with visits/requirements. Adolescents: participant and parent/legal guardian (as applicable) voluntarily provide written informed consent/assent and can communicate with investigator and attend scheduled visits.

Exclusion Criteria:

• Presence of other skin diseases or skin infections that may interfere with AD assessment at screening/baseline, or large tattoos, birthmarks, or scars over AD lesions at screening/baseline.

Unstable AD, or continuously requiring potent topical corticosteroids to control signs/symptoms.

AD lesions located only or mainly on hands, feet, scalp, face, or genitals with no history of classic flexural involvement.

Known/suspected allergy to any component of study cream or its vehicle, or moderate-to-severe allergic disease at IC signing (e.g., food/drug/detergent allergy; AD-related allergy allowed); or history of moderate-to-severe allergic disease.

Use of any of the following prior to study drug:

Any systemic or topical JAK inhibitor before study entry; Biologics affecting AD (e.g., anti-IL-4, IL-5, IL-12/23, IL-13, IL-31, CD20, TNF-α, IgE) within 12 weeks or 5 half-lives (whichever longer) before study drug; Systemic immunosuppressants/immunomodulators (cyclosporine, MTX, azathioprine, MMF), oral/systemic corticosteroids, PDE4 inhibitors within 4 weeks or 5 half-lives (whichever longer); Systemic herbal/Chinese medicine for AD or other autoimmune-inflammatory diseases within 4 weeks; Phototherapy (NBUVB, UVB, UVA1, PUVA), tanning bed, or other light-emitting device within 4 weeks; Any topical AD treatment (except non-medicated emollient) or antihistamines within 1 week (stable-dose antihistamine before screening allowed); Participation in another clinical trial within 4 weeks or 5 half-lives of investigational product (whichever longer); Any vaccination within 4 weeks, BCG within 1 year, or planned live/attenuated vaccine during study; Long-acting anticoagulants (warfarin, dabigatran) within 4 weeks or need for continuous anticoagulation (aspirin ≤100 mg/day allowed); Strong CYP3A4 inhibitors/inducers (rifampin, fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole, nefazodone) within 2 weeks or 5 half-lives; Allergen-specific immunotherapy within 6 months. Major surgical procedure within 12 weeks before screening. Serious infectious disease within 6 months; history of zoster or disseminated zoster; any infection requiring antibiotics within 2 weeks before screening; or active acute/chronic/local infection at screening; or infection judged by investigator likely to worsen with participation.

Active tuberculosis, untreated latent TB, or incompletely cured TB (by history, symptoms, labs, IGRA, imaging).

Conditions negatively affecting immune response (e.g., organ transplant), or known immunodeficiency (acquired, genetic, or drug-induced).

NYHA Class III/IV heart failure; unstable angina; stroke/TIA; MI; CABG/PCI history; uncontrolled hypertension (SBP >160 or DBP >100 mmHg); hypotension (SBP <90 or DBP <60); clinically significant electrolyte disorder; or other unstable disease affecting safety.

History of thromboembolic event (DVT, pulmonary embolism, CVA) or known genetic hypercoagulable state.

Clinically relevant severe pulmonary disease (e.g., pulmonary hypertension, acute COPD exacerbation, pneumothorax).

Severe GI disease (peptic ulcer, obstruction) or condition affecting drug absorption (e.g., gastrectomy).

Severe hematologic disease (moderate/severe anemia, proliferative bone marrow disease, thrombocytopenia, hemoglobinopathy), severe coagulation abnormality, or high thrombotic risk.

Malignant tumor or lymphoproliferative disease within past 10 years, except adequately treated non-melanoma skin cancer or cervical intraepithelial neoplasia.

Screening 12-lead ECG with prolonged QTcF (>450 ms male, >470 ms female), family history of long QT, or chronic use of QT-prolonging drugs.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 4% JYP0066 topical cream - applied twice daily (BID) to affected skin areas for 8 weeks	Drug: JYP0066 4% topical cream; applied twice daily (BID) to affected skin areas for 8 weeks
Experimental: 3% JYP0066 topical cream - applied twice daily (BID) for 8 weeks	Drug: 3% JYP0066 topical cream; applied twice daily (BID) for 8 weeks
Experimental: 2% JYP0066 topical cream - applied twice daily (BID) for 8 weeks	Drug: 2% JYP0066 topical cream; applied twice daily (BID) for 8 weeks
Placebo Comparator: Matching placebo cream (vehicle, no active ingredient) - applied twice daily (BID) for 8 weeks	Drug: Matching placebo cream (vehicle, no active ingredient); applied twice daily (BID) for 8 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Percent change from baseline in EASI score at Week 8	Baseline to Week 8

Secondary Outcome Measures

Outcome Measure	Time Frame
Proportion of participants achieving EASI 50/75/90 at Weeks 1, 2, 4, and 8	Weeks 1, 2, 4, 8
Percent change from baseline in EASI score at Weeks 1, 2, and 4	Weeks 1, 2, 4
Proportion of participants with vIGA-AD response at Weeks 1, 2, 4, 8	Weeks 1, 2, 4, 8
Proportion of participants with vIGA-AD score 0/1 at Weeks 1, 2, 4, 8	Weeks 1, 2, 4, 8
Proportion of participants with ≥2-point improvement in vIGA-AD from baseline at Weeks 1, 2, 4, 8	Weeks 1, 2, 4, 8

Collaborators and Investigators

• Sponsor: Guangzhou JOYO Pharma Co., Ltd

Study record dates

Study Major Dates

• Study Start (Estimated): September 30, 2026
• Primary Completion (Estimated): August 30, 2027
• Study Completion (Estimated): December 31, 2027

Study Registration Dates

• First Submitted: September 20, 2026
• First Submitted That Met QC Criteria: September 20, 2026
• First Posted (Actual): September 28, 2026

Study Record Updates

• Last Update Posted (Actual): September 30, 2026
• Last Update Submitted That Met QC Criteria: September 27, 2026
• Last Verified: September 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Genetic Diseases, Inborn; Immune System Diseases; Hypersensitivity, Immediate; Hypersensitivity; Skin Diseases; Skin Diseases, Genetic; Skin Diseases, Eczematous; Dermatitis; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases; Dermatitis, Atopic
• Other Study ID Numbers: JYP0066M201

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No